NCT00110994 - Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

March 31, 2008

Conditions

CancerMelanoma

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21

DRUG

Placebo

Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21

DRUG

Dacarbazine

Dacarbazine, 1000 mg/m\^2 intravenous on Study Day 1

Trial Locations (14)

15232

Pittsburgh

28203

Charlotte

33805

Lakeland

60068

Park Ridge

68114

Omaha

78229

San Antonio

80045

Aurora

85724

Tucson

02114

Boston

02115-6084

Boston

02215

Boston

63110-1093

St Louis

29926-2739

Hilton Head Island

37232-6307

Nashville